NRC Health (NRC) reported $143.79M of revenue for the twelve months ended Sep 30, 2026. That is up 3.4% from the year before. Revenue for fiscal 2025 was $137.39M.

Yes. NRC Health earned $6.13M in net income for the twelve months ended Sep 30, 2026, a net margin of 4.3%.

How much cash and debt does NRC have?

NRC Health reported $3.63M in cash and cash equivalents and $102.90M of debt on its most recent balance sheet in SEC filings.

How fast is NRC revenue growing?

NRC Health's revenue changed -4.0% in fiscal 2025, to $137.39M. Its compound annual growth rate was +0.6% over 5 years and +3.0% over 10 years.

What is NRC free cash flow?

NRC Health generated $18.45M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $23.77M less capital expenditures.

What is NRC earnings per share?

Diluted earnings per share were $49.78 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did NRC last report financial results?

The latest statements here come from NRC Health's 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.

Where does this NRC financial data come from?

Quantisnow builds these statements from the structured XBRL data NRC Health files with the SEC. It is provided for information only and is not investment advice.

Financials · NRC

NRC Health (NRC) financials

For the twelve months ended Sep 30, 2026, NRC Health reported $143.79M of revenue and $6.13M of net income.

Revenue, TTM: $143.79M
Revenue growth, YoY: +3.4%
Net income, TTM: $6.13M
Net income growth, YoY: -62.5%
Net margin: 4.3%
Free cash flow, TTM: $18.45M
EPS, diluted, TTM: $49.78
Cash: $3.63M
Total debt: $102.90M
P/E: 89.46
P/S: 3.82
Market cap: $548.7M

Annual revenue$137.39M

FY2016FY2025

Annual net income$11.29M

FY2016FY2025

Annual free cash flow$15.74M

FY2016FY2025

NRC revenue and earnings growth

NRC revenueQ3 2026$38.40M

Quarter YoY: +11.0%
QoQ: +8.5%
FY YoY: -4.0%
5Y CAGR: +0.6%
10Y CAGR: +3.0%

NRC revenue was $38.40M in fiscal Q3 2026 (ended Sep 30, 2026), up 11.0% from a year earlier and up 8.5% from the prior quarter. For the full fiscal 2025 it was $137.39M, down 4.0% from fiscal 2024. Compound annual growth was +0.6% over 5 years and +3.0% over 10 years. It rose in 7 of the last 10 fiscal years.

NRC net incomeQ3 2026$4.70M

Quarter YoY: +14.1%
FY YoY: -54.4%
5Y CAGR: -21.2%
10Y CAGR: -4.3%

NRC net income was $4.70M in fiscal Q3 2026 (ended Sep 30, 2026), up 14.1% from a year earlier. For the full fiscal 2025 it was $11.29M, down 54.4% from fiscal 2024. Compound annual growth was -21.2% over 5 years and -4.3% over 10 years. It rose in 6 of the last 10 fiscal years.

NRC EPSQ3 2026$0.21

Quarter YoY: +16.7%
FY YoY: 48x
5Y CAGR: +103.0%

NRC diluted EPS was $0.21 in fiscal Q3 2026 (ended Sep 30, 2026), up 16.7% from a year earlier. For the full fiscal 2025 it was $50.00, up about 48-fold from fiscal 2024. Compound annual growth was +103.0% over 5 years.

NRC free cash flowQ3 2026$6.98M

Quarter YoY: -31.4%
QoQ: 113x
FY YoY: -17.9%
5Y CAGR: -15.5%
10Y CAGR: -1.8%

NRC free cash flow was $6.98M in fiscal Q3 2026 (ended Sep 30, 2026), down 31.4% from a year earlier and up about 113-fold from the prior quarter. For the full fiscal 2025 it was $15.74M, down 17.9% from fiscal 2024. Compound annual growth was -15.5% over 5 years and -1.8% over 10 years. It rose in 6 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$137.39M	$143.06M	$148.58M	$151.57M	$147.95M	$133.28M	$127.98M	$119.69M	$117.56M	$109.38M
Selling, general and admin	$54.80M	$44.91M	$46.62M	$42.70M	$38.96M	$34.44M	$32.97M	$31.37M	$29.69M	$28.39M
Operating income	$22.59M	$35.19M	$40.05M	$46.54M	$50.27M	$42.68M	$43.03M	$35.27M	$34.22M	$31.20M
Interest expense	$4.76M	$2.60M	$862.0K	$1.21M	$1.67M	$1.81M	$2.09M	$1.51M	$82.0K	$190.0K
Pre-tax income	$17.84M	$32.69M	$39.96M	$42.81M	$48.62M	$41.47M	$40.52M	$34.71M	$34.28M	$31.36M
Income tax	$6.25M	$7.91M	$8.99M	$11.02M	$11.15M	$4.21M	$8.11M	$4.66M	$11.34M	$10.84M
Net income	$11.29M	$24.78M	$30.96M	$31.78M	$37.45M	$37.20M	$32.41M	$30.05M	$22.94M	$20.52M
EPS, basic	$50.00	$1.05	$1.26	$1.28	$1.47	$1.48	$1.30	-	-	-
EPS, diluted	$50.00	$1.04	$1.25	$1.27	$1.46	$1.45	$1.26	-	-	-
Diluted shares	22.4M	23.7M	24.7M	25.1M	25.6M	25.7M	25.7M	-	-	-

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$4.14M	$4.23M	$6.65M	$25.03M	$54.36M	$34.69M	$13.52M	$12.99M	$34.73M	$33.02M
Receivables	$11.11M	$11.05M	$12.38M	$14.46M	$13.73M	$13.92M	$11.64M	$11.92M	$14.81M	$10.86M
Current assets	$20.21M	$19.60M	$24.36M	$43.72M	$73.71M	$54.11M	$29.16M	$28.41M	$52.26M	$47.06M
Goodwill	$66.15M	$66.15M	$61.61M	$61.61M	$61.61M	$57.26M	$57.94M	$57.83M	$58.02M	$57.86M
Total assets	$134.88M	$132.54M	$122.44M	$130.46M	$157.54M	$133.42M	$110.69M	$108.03M	$127.32M	$120.62M
Current liabilities	$36.62M	$35.86M	$36.20M	$33.42M	$40.39M	$31.68M	$38.16M	$47.11M	$32.31M	$31.51M
Short-term debt	$4.01M	-	-	-	-	-	-	-	$1.07M	$2.68M
Long-term debt	$75.02M	$57.90M	$29.47M	-	-	$26.55M	$29.80M	$34.18M	-	$857.0K
Total debt	$79.03M	$57.90M	$29.47M	$22.32M	$26.62M	$26.55M	$29.80M	$34.18M	$1.07M	$3.54M
Total liabilities	$120.89M	$101.25M	$73.48M	$58.43M	$72.20M	$69.11M	$77.79M	$88.95M	$37.27M	$37.82M
Shareholders' equity	$13.99M	$31.28M	$48.95M	$72.03M	$85.34M	$64.31M	$32.89M	$19.08M	$90.04M	$82.81M

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$26.45M	$34.63M	$38.11M	$36.27M	$46.34M	$40.64M	$40.92M	$39.85M	$28.09M	$26.84M
Capital expenditures	$10.71M	$15.45M	$15.78M	$9.84M	$5.51M	$3.98M	$4.66M	$5.97M	$4.57M	$3.97M
Free cash flow	$15.74M	$19.18M	$22.33M	$26.43M	$40.83M	$36.65M	$36.26M	$33.88M	$23.52M	$22.87M
Investing cash flow	-$10.71M	-$20.28M	-$15.78M	-$9.84M	-$8.51M	-$3.72M	-$4.66M	-$5.97M	-$6.12M	-$3.75M
Financing cash flow	-$15.84M	-$16.76M	-$40.71M	-$55.58M	-$18.16M	-$15.50M	-$36.35M	-$54.50M	-$21.12M	-$32.50M
Dividends paid	$10.98M	$11.45M	$36.37M	$20.96M	$9.16M	$10.52M	$31.30M	$16.86M	$16.87M	$28.55M
Share repurchases	$20.18M	$30.95M	$19.10M	$27.62M	$4.14M	-	-	-	-	-
Stock-based compensation	$3.31M	$284.0K	$935.0K	$1.20M	$623.0K	$680.0K	$1.22M	$1.51M	$1.84M	$1.93M
Depreciation and amortization	$7.62M	$6.02M	$5.90M	-	-	-	$5.54M	$5.46M	$4.59M	$4.22M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	-4.0%	-3.7%	-2.0%	2.4%	11.0%	4.1%	6.9%	1.8%	7.5%	6.9%
Net income growth, YoY	-54.4%	-20.0%	-2.6%	-15.1%	0.7%	14.8%	7.9%	31.0%	11.8%	16.5%
EPS growth, YoY	4707.7%	-16.8%	-1.6%	-13.0%	0.7%	15.1%	-	-	-	-
Operating margin	16.4%	24.6%	27.0%	30.7%	34.0%	32.0%	33.6%	29.5%	29.1%	28.5%
Net margin	8.2%	17.3%	20.8%	21.0%	25.3%	27.9%	25.3%	25.1%	19.5%	18.8%
Free cash flow margin	11.5%	13.4%	15.0%	17.4%	27.6%	27.5%	28.3%	28.3%	20.0%	20.9%
Return on equity	80.7%	79.2%	63.2%	44.1%	43.9%	57.8%	98.5%	157.5%	25.5%	24.8%
Return on assets	8.4%	18.7%	25.3%	24.4%	23.8%	27.9%	29.3%	27.8%	18.0%	17.0%
Current ratio	0.55	0.55	0.67	1.31	1.82	1.71	0.76	0.60	1.62	1.49
Debt to equity	5.65	1.85	0.60	0.31	0.31	0.41	0.91	1.79	0.01	0.04

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$38.40M	$35.39M	$34.80M	$35.19M	$34.61M	$34.04M	$33.55M	$36.91M	$35.82M	$35.02M	$35.31M	$38.00M
Selling, general and admin	$12.04M	$22.95M	$13.42M	$14.45M	$12.27M	$17.73M	$10.36M	$11.45M	$10.99M	$11.22M	$11.25M	$11.07M
Operating income	$8.91M	-$3.24M	$5.57M	$4.67M	$7.74M	$1.59M	$8.60M	$9.59M	$7.98M	$8.87M	$8.76M	$11.71M
Interest expense	$1.53M	$1.32M	$1.25M	$1.37M	$1.46M	$1.03M	$899.0K	$729.0K	$706.0K	$555.0K	$605.0K	$268.0K
Pre-tax income	$7.40M	-$4.54M	$4.38M	$3.27M	$6.27M	$581.0K	$7.72M	$8.88M	$7.30M	$8.32M	$8.19M	$11.47M
Income tax	$2.70M	-$1.25M	$1.16M	$1.47M	$2.15M	$687.0K	$1.94M	$2.31M	$1.61M	$2.15M	$1.83M	$2.61M
Net income	$4.70M	-$3.28M	$3.22M	$1.49M	$4.12M	-$106.0K	$5.79M	$6.56M	$5.69M	$6.17M	$6.36M	$8.86M
EPS, basic	$0.22	-$0.15	$0.14	$49.58	$0.18	-$0.01	$0.25	$0.28	$0.24	$0.26	$0.27	$0.36
EPS, diluted	$0.21	-$0.15	$0.14	$49.58	$0.18	-$0.01	$0.25	$0.27	$0.24	$0.26	$0.27	$0.36
Diluted shares	21.9M	22.0M	21.9M	-	22.1M	22.7M	23.0M	-	23.7M	23.9M	24.0M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$3.63M	$3.33M	$2.55M	$4.14M	$2.22M	$5.27M	$2.50M	$4.23M	$3.46M	$485.0K	$1.70M	$6.65M
Receivables	$15.34M	$9.32M	$10.83M	$11.11M	$12.75M	$12.42M	$11.33M	$11.05M	$11.06M	$10.06M	$11.13M	$12.38M
Current assets	$26.71M	$22.81M	$19.98M	$20.21M	$20.40M	$25.32M	$20.40M	$19.60M	$20.70M	$16.95M	$20.01M	$24.36M
Goodwill	$66.15M	$66.15M	$66.15M	$66.15M	$66.15M	$66.15M	$66.15M	$66.15M	$66.21M	$61.61M	$61.61M	$61.61M
Total assets	$139.21M	$136.15M	$134.56M	$134.88M	$135.72M	$141.39M	$135.18M	$132.54M	$131.80M	$119.10M	$120.91M	$122.44M
Current liabilities	$41.84M	$35.02M	$38.47M	$36.62M	$38.57M	$35.93M	$37.77M	$35.86M	$44.28M	$45.73M	$48.85M	$36.20M
Short-term debt	$4.77M	$4.02M	-	$4.01M	-	-	-	-	-	-	-	-
Long-term debt	$98.13M	$86.01M	$74.02M	$75.02M	$76.03M	$77.03M	$58.67M	$57.90M	$44.91M	$25.66M	$27.57M	$29.47M
Total debt	$102.90M	$90.03M	$74.02M	$79.03M	$76.03M	$77.03M	$58.67M	$57.90M	$44.91M	$25.66M	$27.57M	$29.47M
Total liabilities	$148.34M	$129.60M	$121.06M	$120.89M	$121.41M	$120.06M	$105.50M	$101.25M	$97.17M	$78.90M	$83.97M	$73.48M
Shareholders' equity	-$9.12M	$6.55M	$13.49M	$13.99M	$14.31M	$21.33M	$29.67M	$31.28M	$34.62M	$40.20M	$36.95M	$48.95M

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$8.02M	$1.39M	$7.18M	$7.18M	$13.76M	-$1.14M	$6.65M	$6.38M	$9.42M	$6.79M	$12.04M	$11.71M
Capital expenditures	$1.04M	$1.32M	$1.83M	$1.12M	$3.59M	$3.01M	$2.99M	$4.44M	$1.60M	$5.27M	$4.14M	$3.77M
Free cash flow	$6.98M	$62.0K	$5.35M	$6.06M	$10.18M	-$4.15M	$3.66M	$1.94M	$7.83M	$1.52M	$7.90M	$7.94M
Investing cash flow	-$1.04M	-$1.32M	-$1.83M	-$1.12M	-$3.59M	-$3.01M	-$2.99M	-$4.44M	-$6.43M	-$5.27M	-$4.14M	-$3.77M
Financing cash flow	-$6.68M	$718.0K	-$6.94M	-$4.14M	-$13.23M	$6.92M	-$5.39M	-$1.16M	-$17.0K	-$2.73M	-$12.85M	-$5.11M
Dividends paid	$3.54M	$3.61M	$3.63M	$2.70M	$2.78M	$2.73M	$2.77M	$2.82M	$2.86M	$2.87M	$2.91M	$2.95M
Share repurchases	$15.98M	$7.64M	$1.94M	$1.0K	$9.27M	$5.99M	$4.92M	$7.40M	$8.55M	$0	$15.00M	$15.00M
Stock-based compensation	-$135.0K	$7.37M	$1.61M	$1.91M	$925.0K	$307.0K	$171.0K	$188.0K	$189.0K	-$57.0K	-$36.0K	$258.0K
Depreciation and amortization	$2.07M	$2.12M	$2.17M	$2.15M	$2.19M	$1.74M	$1.54M	$1.52M	$1.55M	$1.51M	$1.45M	$1.43M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	11.0%	4.0%	3.7%	-4.6%	-3.4%	-2.8%	-5.0%	-2.9%	-5.6%	-3.2%	-3.2%	-0.4%
Net income growth, YoY	14.1%	-	-44.3%	-77.3%	-27.5%	-	-9.0%	-25.9%	-27.8%	-15.1%	-8.7%	33.4%
EPS growth, YoY	16.7%	-	-44.0%	-	-25.0%	-	-7.4%	-25.0%	-25.0%	-10.3%	-3.6%	33.3%
Operating margin	23.2%	-9.1%	16.0%	13.3%	22.4%	4.7%	25.6%	26.0%	22.3%	25.3%	24.8%	30.8%
Net margin	12.3%	-9.3%	9.3%	4.2%	11.9%	-0.3%	17.2%	17.8%	15.9%	17.6%	18.0%	23.3%
Free cash flow margin	18.2%	0.2%	15.4%	17.2%	29.4%	-12.2%	10.9%	5.2%	21.8%	4.3%	22.4%	20.9%
Current ratio	0.64	0.65	0.52	0.55	0.53	0.70	0.54	0.55	0.47	0.37	0.41	0.67
Debt to equity	-	13.75	5.48	5.65	5.31	3.61	1.98	1.85	1.30	0.64	0.75	0.60

Source: XBRL data NRC Health files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NRC peers

Company	Revenue	Growth	Net income	Net margin	Market cap
NRC	$143.79M	+3.4%	$6.13M	4.3%	$548.7M
IQVIQVIA Holdings Inc.	$17.31B	+8.8%	$1.40B	8.1%	$44.80B
INCYIncyte Corp.	$6.01B	+24.9%	$403.41M	6.7%	$24.39B
MEDPMedpace Holdings Inc.	$2.84B	+20.4%	$517.83M	18.2%	$18.27B
CRLCharles River Laboratories International Inc.	$3.98B	-1.2%	$40.19M	1.0%	$16.17B
ICLRICON plc	$8.25B	+0.8%	$229.34M	2.8%	$15.68B
ABSIAbsci Corporation	$1.56M	-62.3%	-$121.08M	-7756.4%	$1.75B
OABIOmniAb Inc.	$40.21M	+90.6%	-$43.47M	-108.1%	$732.9M
MXCTMaxCyte Inc.	$31.05M	-13.2%	-$35.64M	-114.8%	$130.0M

NRC FAQ

8 questions

What is NRC revenue?
NRC Health (NRC) reported $143.79M of revenue for the twelve months ended Sep 30, 2026. That is up 3.4% from the year before. Revenue for fiscal 2025 was $137.39M.
Is NRC profitable?
Yes. NRC Health earned $6.13M in net income for the twelve months ended Sep 30, 2026, a net margin of 4.3%.
How much cash and debt does NRC have?
NRC Health reported $3.63M in cash and cash equivalents and $102.90M of debt on its most recent balance sheet in SEC filings.
How fast is NRC revenue growing?
NRC Health's revenue changed -4.0% in fiscal 2025, to $137.39M. Its compound annual growth rate was +0.6% over 5 years and +3.0% over 10 years.
What is NRC free cash flow?
NRC Health generated $18.45M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $23.77M less capital expenditures.
What is NRC earnings per share?
Diluted earnings per share were $49.78 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did NRC last report financial results?
The latest statements here come from NRC Health's 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.
Where does this NRC financial data come from?
Quantisnow builds these statements from the structured XBRL data NRC Health files with the SEC. It is provided for information only and is not investment advice.